ImetelChat

What really injured investors was STATS “flimsy data “ report -- short attack-
And then Janssen pump and dump by posting all sorts of bullish market revenue probabilities for mds and MF with Imet then saying sorry we will discontinue as we have other priorities
not saying the drug was bad just other ...

you should also mention how it was very strange that janssen dropped Geron
with a non continuation decision after the drug was offered on compassionate use and that janssen hired people to
sell imet and work on pricing of the drug per linkend ....... and that janssen 1 month prior had it on the ...